Industri Jamu dan Farmasi Sido Muncul Tbk PT
Industri Jamu dan Farmasi Sido Muncul Tbk PT is a pharmaceutical company that produces and distributes traditional herbal medicines and pharmaceutical products in Indonesia.
Business. Industri Jamu dan Farmasi Sido Muncul Tbk PT (SIDO.JK) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in Indonesia and is primarily listed on the Jakarta Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Industri Jamu dan Farmasi Sido Muncul Tbk PT (SIDO.JK) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in Indonesia and is primarily listed on the Jakarta Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not available.
The company maintains a strong liquidity position with a current ratio of 3.86, indicating that it has sufficient current assets to cover its current liabilities. The company's liquidity is further supported by a cash and equivalents balance of 7,365,000,000 IDR, which provides a buffer for short-term obligations. The company's debt-to-equity ratio is 0.0, suggesting that it is not leveraged and relies primarily on equity financing.
In terms of profitability, the company demonstrates a return on equity (ROE) of 39.39% and a return on assets (ROA) of 33.39%, both of which are strong indicators of efficient use of equity and assets to generate profits. The company's operating income of 1,544,117,000,000 IDR and net income of 1,229,202,000,000 IDR reflect its ability to maintain profitability despite the competitive nature of the pharmaceutical industry.
The company's revenue is primarily concentrated in Indonesia, with a significant portion derived from the domestic market. The company's exposure to geographic and segment-specific risks is limited, as it operates within a single primary market and product line. The company's revenue concentration in Indonesia may pose a risk if there are adverse changes in the domestic economic or regulatory environment.
The company's growth trajectory is supported by its strong operating cash flow of 1,253,401,000,000 IDR and free cash flow of 179,570,000,000 IDR, which provide flexibility for reinvestment and expansion. The company's capital expenditure of -61,984,000,000 IDR indicates that it is not currently investing heavily in new assets, which may suggest a focus on maintaining existing operations rather than aggressive expansion.
The company's risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves further support its low liquidity risk profile. The company's dilution risk is also low, as there are no indications of potential share dilution through new issuances or convertible instruments.
Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's strong financial performance and low risk profile suggest that it is well-positioned to maintain its market position and continue generating value for shareholders.
- The company has a strong liquidity position with a current ratio of 3.86 and a cash and equivalents balance of 7,365,000,000 IDR.
- The company demonstrates high profitability with a return on equity of 39.39% and a return on assets of 33.39%.
- The company's revenue is primarily concentrated in Indonesia, which may pose a risk if there are adverse changes in the domestic economic or regulatory environment.
- The company's growth trajectory is supported by strong operating and free cash flows, indicating financial flexibility for reinvestment and expansion.
- The company's risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected.
- "margin_outlook_rationale": "The company's strong profitability, as indicated by its high return on equity and return on assets, suggests that it is likely to maintain or improve its margins in the near term.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 41,39 |
| Revenue | —no estimate | —no estimate | 4,22T IDR |
| Operating income | —no estimate | —no estimate | 1,55T IDR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Industri Jamu dan Farmasi Sido Muncul Tbk PT Market data — financials · 2026-05-29
- Industri Jamu dan Farmasi Sido Muncul Tbk PT Market data — analyst estimates · 2026-05-29
- Industri Jamu dan Farmasi Sido Muncul Tbk PT Market data — ESG · 2026-05-29